Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19 | Zendy

Tony Y. Zhang | Zendy; Boyu Zhong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19

Author(s) -

Tony Y. Zhang,

Boyu Zhong

Publication year - 2020

Publication title -

medicine in drug discovery

Language(s) - English

Resource type - Journals

ISSN - 2590-0986

DOI - 10.1016/j.medidd.2020.100036

Subject(s) - hydroxychloroquine , covid-19 , business , supply and demand , pandemic , pharmaceutical industry , medicine , virology , economics , pharmacology , disease , pathology , outbreak , infectious disease (medical specialty) , microeconomics

This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research